Macau Society of Clinical Oncology

Moving to a new standard: Perspectives on DLBCL disease management


Thank your for your time!

Q1. What is the portion of relapse/refractory DLBCL patients who are eligible for ASCT?

“High-dose chemotherapy and ASCT have historically been shown to provide the best chance of cure for patients with chemotherapy sensitive relapse. However, due to advanced age and comorbidities, only half of all patients are eligible for such an intensive approach, and of these transplant-eligible patients, only half will prove to be

chemosensitive to salvage therapy and proceed to transplant, of which less than half will be cured.” 

(Laurie H. Sehn, Randy D. Gascoyne; Blood (2015) 125 (1): 22–32.)

Q2. What is the pooled response rate for the patient with R/R DLBCL in SCHOLAR-1 patient-level retrospective analysis?

“Response rates were similar across the 4 data sets, ranging from 20% to 31%, with a pooled response rate of 26%. CR rates ranged from 2% to 15%, with a pooled CR rate of 7%. Pooled response rates by refractory subgroup (primary refractory, refractory to second-line or later-line therapy, and relapsed ≤12 months after ASCT) ranged from 20% to 39%. Response rates were consistently low across all subgroups, with the lowest response rates in the primary refractory and high-risk IPI subgroups 

(Crump M. et al.; Blood (2017) 130 (16): 1800–1808.)

Q3. Which surface antigen on B-cell does polatuzumab bind to?

Here we describe the development and activity of anti–CD79bvcMMAE, an ADC targeted to CD79b in preclinical NHL models. We show that anti–CD79b-vcMMAE has profound activity across a broad range of lymphoma cell lines and molecular subtypes.

(David Dornan et al.; Blood (2009) 114 (13): 2721–2729.)

Q4. What is the treatment arm regimen for GO29365 in phase 2 randomisation?

(L. Sehn et al.; Journal of Clinical Oncology 38, no. 2 (January 10, 2020) 155-165.)

Q5. What is the complete response rate of the Pola-BR arm vs BR arm in GO29365 study?

“The primary analysis for the randomly assigned cohort showed significantly higher IRC-assessed CR rates at EOT with pola-BR versus BR (40.0% v 17.5%; P = .026;), with . 90% concordance between the IRC and investigator.”

(L. Sehn et al.; Journal of Clinical Oncology 38, no. 2 (January 10, 2020) 155-165.)